Obesity News

A low-carbohydrate diet that emphasized high-quality protein, fat and carbohydrates from healthful plant-based sources was linked to less weight gain over a 4-year period, according to a recent study.

About two-thirds of adults who were prescribed an obesity medication stop taking them after 6 months, and 80% discontinued use at 1 year, according to a retrospective cohort study.

The SELECT trial, which showed semaglutide, a GLP-1 receptor agonist also approved for diabetes, reduced CV events in people with overweight/obesity and CVD but no diabetes, was one of the most important developments in cardiology in 2023.

According to a recent study, more than half of the United States population eligible for semaglutide could lose at least 15% of their body weight after treatment with the medication.

Women who quit smoking and were treated with the GLP-1 receptor agonist dulaglutide were less likely to experience substantial weight gain compared with those who received placebo, according to researchers.

Adults with obesity can achieve 15% or more weight loss with nutrient-stimulated, hormone-based therapies, but treating obesity involves more than just reducing a person’s body weight, an expert said.

An analysis of global conversations involving more than 1,600 health care professionals on social media in November has revealed collective optimism in response to the approval of a new weight-management option for adults with obesity.

The AMA has adopted a policy in support of insurance coverage parity for evidence-based weight-loss medications “without exclusions or additional carve-outs,” the organization recently announced.

Adolescents and young adults who partake in more light physical activity have lower cholesterol levels, according to a study published in The Journal of Clinical Endocrinology & Metabolism.

Findings from two cardiovascular outcome trials revealed that targeting obesity could become a major focus for treating cardiovascular disease and heart failure with preserved ejection fraction in the future, according to a speaker.